• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Payers

Latest News

FDA approved - Image credit: wladimir1804 - stock.adobe.com
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024

Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.

Duchenne | Image credit: hafakot – stock.adobe.com
Agamree Now Commercially Available to Treat Duchenne Muscular Dystrophy

March 19th 2024

Concept of FDA approved | Image credit: wladimir1804 - stock.adobe.com
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL

March 19th 2024

Stethoscope with cash and credit | Image Credit: © adragan - stock.adobe.com
Reducing Low-Value Care Is Hard, but What About Just Not Paying for It?

March 14th 2024

AMA President Blasts Payers’ Response to Cyberattack
AMA President Blasts Payers’ Response to Cyberattack

March 14th 2024

More News

© 2024 MJH Life Sciences
AJMC®
All rights reserved.